OpenResearchAlpha

bioRxiv · 3 Nov 2026

Anti-TGFβ peptide P144 augments CAR-T cell efficacy through neutrophil recruitment and TME remodeling in malignant mesothelioma

R. Bugda, E. Hawkins, G. Box, F. Secchiari, C. Leboreiro Babe, R. S. Tan, P. Dimou, R. R. D'Souza, A. Klampatsa

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Malignant mesothelioma is a rare, aggressive and highly desmoplastic cancer characterised by a profoundly immunosuppressive tumour microenvironment (TME). Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, but its activity against solid tumours such as mesothelioma remains limited, in part through transforming growth factor-beta (TGF{beta})-mediated immunosuppression. To address this barrier, we engineered murine CAR-T cells that simultaneously target tumour antigen and deliver TGF{beta} blockade to the tumour. We first compared two anti-TGF{beta} peptides, the beta glycan-derived P144 and the phage-display-derived P17, in vitro; both attenuated TGF{beta}-induced epithelial-to-mesenchymal transition and reporter activity, but P144 suppressed canonical Smad3 phosphorylation more effectively and was selected for downstream work. Murine CAR constructs targeting either mesothelin (M11) or fibroblast activation protein (FAP) were modified to secrete P144, and the resulting products were assessed in co-culture assays and in the syngeneic AE17m model of mesothelioma. P144 secretion did not alter transduction efficiency, expansion or antigen-specific cytotoxicity, but markedly increased antigen-driven IFN{gamma} production, most notably at low effector-to-target ratios. In vivo, both M11-P144 and FAP-P144 CAR-T cells-controlled tumour growth better than their parental, peptide-free counterparts, although complete tumour resolution was not achieved. Flow cytometric profiling of the tumour immune infiltrate showed that P144 delivery increased intratumoral neutrophil frequency approximately three-fold, and neutrophils recovered from these tumours were substantially more cytotoxic ex vivo than those from control tumours. Antibody-mediated neutrophil depletion attenuated the additional benefit conferred by P144 while leaving parental CAR-T activity largely intact, indicating that neutrophils contribute functionally to the effect. Local, CAR-T-delivered TGF{beta} blockade therefore remodels the mesothelioma TME and engages a tumoricidal neutrophil response, offering a modular strategy for enhancing adoptive cell therapy in desmoplastic solid tumours.

Immunology

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (9)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.